GlassScriptPhysician profile
William R Walker
NPI 1427390905
$4,766.99
in general payments reported to CMS, 2019-2025
20 companies · $1,115 in 2025
The $1,115 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $480 · 2023: $1,217 · 2024: $1,954 · 2025: $1,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,197 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,196.55 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,113.19 | 2022-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $568.95 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $379.73 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $372.23 | 2022-2025 | Farxiga, Brilinta, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $342.58 | 2022-2025 | |
| Astellas Pharma US INC | $333.93 | 2022-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $326.84 | 2024-2025 | |
| Lilly USA, LLC | $292.06 | 2022-2024 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $276.59 | 2022-2025 | Otezla, Repatha, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.41 | 2023-2025 | Jardiance, Tradjenta |
| Takeda Pharmaceuticals U.S.A., INC. | $105.90 | 2022-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.93 | 2023-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $89.13 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Tanabe Pharma America, INC. | $70.52 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $46.51 | 2022-2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $31.08 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $23.23 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.50 | 2023 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $18.53 | 2022 | |
| Organon LLC | $18.15 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.